Ascendis Pharma A ASND Institutional Ownership

Updated Oct 11, 2026

Ascendis Pharma A/S (NASDAQ:ASND) counted 308 institutional investors among its 13F-reported shareholders for the quarter ended June 30, 2026.

• Total shares held in Ascendis Pharma rose 7.39% versus Q1 2026, while the number of holders rose 26.23% versus Q2 2025.
• Of the 308 holders, 298 added to their positions, 4 reduced their stakes and 6 left their positions unchanged in Q2 2026.
• The aggregate institutional position in Ascendis Pharma was 66.88Mn shares at the end of Q2 2026, up 4.6Mn from the prior quarter and up 4.83Mn from a year earlier.
• As of June 30, 2026, Ra Capital Management, L.P. held the largest stake in Ascendis Pharma with 10.28Mn shares.
• Among holders that already owned Ascendis Pharma, the biggest buyers in Q2 2026 were T. Rowe Price Investment Management, Inc. (+592.8K shares), State Street Corp (+426.63K shares), Frazier Life Sciences Management, L.P. (+91.82K shares), Public Employees Retirement System of Ohio (+14.19K shares) and IFP Advisors, Inc (+419 shares).
• Holders that trimmed the most shares of Ascendis Pharma in Q2 2026 while keeping a position were T. Rowe Price Associates Inc (-407.82K shares), Driehaus Capital Management LLC (-57.5K shares), Ninepoint Partners LP (-5.4K shares) and Evolutionary Tree Capital Management, LLC (-3.02K shares).
• Business Quant data shows the 10 biggest positions in Ascendis Pharma as of Q2 2026 were held by Ra Capital Management, L.P. (10.28Mn shares), T. Rowe Price Investment Management, Inc. (6.75Mn shares), Avoro Capital Advisors LLC (5.11Mn shares), Westfield Capital Management Co LP (4.8Mn shares), Jupiter Topco LLC (3.65Mn shares), FMR LLC (3.55Mn shares), Artisan Partners Limited Partnership (2.63Mn shares), BlackRock, Inc. (2.21Mn shares), Capital International Investors (1.99Mn shares) and Massachusetts Financial Services Co (1.88Mn shares).